| Followers | 499 |
| Posts | 10140 |
| Boards Moderated | 0 |
| Alias Born | 04/28/2014 |
Sunday, October 07, 2018 9:38:21 PM
Recent INCY News
- Incyte gibt die FDA-Zulassung von Jakafi XR™ (Ruxolitinib) Retardtabletten zur Behandlung von Myelofibrose, Polycythaemia vera und Graft-versus-Host-Erkrankung bekannt • Business Wire • 05/03/2026 01:50:00 PM
- Incyte annonce l’autorisation par la FDA des comprimés à libération prolongée Jakafi XR™ (ruxolitinib) pour le traitement de la myélofibrose, de la polycythémie vraie et de la maladie du greffon contre l’hôte • Business Wire • 05/03/2026 01:50:00 PM
- Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease • Business Wire • 05/01/2026 09:28:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 02:30:26 PM
- Incyte to Present at Upcoming Investor Conferences • Business Wire • 04/29/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:26:36 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:25:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/28/2026 08:02:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 11:03:17 AM
- Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer • Business Wire • 04/28/2026 11:00:00 AM
- Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates • Business Wire • 04/28/2026 11:00:00 AM
- Incyte präsentiert neue Phase-3-Daten zu Tafasitamab auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) • Business Wire • 04/22/2026 10:41:00 AM
- Incyte présente de nouvelles données de phase III sur le tafasitamab au congrès annuel 2026 de l’American Society of Clinical Oncology (ASCO) • Business Wire • 04/22/2026 10:40:00 AM
- インサイト、2026年米国臨床腫瘍学会(ASCO)年次総会でタファシタマブの第3相臨床試験の最新データを発表 • Business Wire • 04/22/2026 10:39:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 08:09:07 PM
- Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting • Business Wire • 04/21/2026 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:13:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:12:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:12:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/17/2026 08:07:44 PM
- Incyte to Report First Quarter Financial Results • Business Wire • 04/09/2026 12:00:00 PM
- Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:10:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:09:54 PM
